354 related articles for article (PubMed ID: 12703659)
1. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
[TBL] [Abstract][Full Text] [Related]
2. Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats.
Arai A; Kannari K; Shen H; Maeda T; Suda T; Matsunaga M
Brain Res; 2003 May; 972(1-2):229-34. PubMed ID: 12711097
[TBL] [Abstract][Full Text] [Related]
3. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Buck K; Ferger B
Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
[TBL] [Abstract][Full Text] [Related]
4. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine.
Mura A; Jackson D; Manley MS; Young SJ; Groves PM
Brain Res; 1995 Dec; 704(1):51-60. PubMed ID: 8750961
[TBL] [Abstract][Full Text] [Related]
5. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
6. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Jonkers N; Sarre S; Ebinger G; Michotte Y
J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
[TBL] [Abstract][Full Text] [Related]
7. Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
Ren LQ; Wienecke J; Hultborn H; Zhang M
J Neurotrauma; 2016 Jun; 33(12):1150-60. PubMed ID: 26830512
[TBL] [Abstract][Full Text] [Related]
8. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Tayarani-Binazir KA; Jackson MJ; Strang I; Jairaj M; Rose S; Jenner P
Behav Pharmacol; 2012 Apr; 23(2):126-33. PubMed ID: 22236652
[TBL] [Abstract][Full Text] [Related]
9. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Sánchez-Pernaute R; Harvey-White J; Cunningham J; Bankiewicz KS
Mol Ther; 2001 Oct; 4(4):324-30. PubMed ID: 11592835
[TBL] [Abstract][Full Text] [Related]
10. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Datla KP; Blunt SB; Dexter DT
Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
[TBL] [Abstract][Full Text] [Related]
11. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y
Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
[TBL] [Abstract][Full Text] [Related]
12. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
13. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Sarre S; De Klippel N; Herregodts P; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jul; 350(1):15-21. PubMed ID: 7935849
[TBL] [Abstract][Full Text] [Related]
15. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
16. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Gil S; Park C; Lee J; Koh H
Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
[TBL] [Abstract][Full Text] [Related]
17. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent.
Fisher A; Biggs CS; Eradiri O; Starr MS
Neuroscience; 2000; 95(1):97-111. PubMed ID: 10619466
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
19. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Buck K; Voehringer P; Ferger B
J Neurochem; 2010 Jan; 112(2):444-52. PubMed ID: 19895663
[TBL] [Abstract][Full Text] [Related]
20. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]